Moreover, a sub-group analysis revealed reduced irisin levels among T2DM patients with osteoporosis compared to diabetics with normal BMDs, suggesting that irisin could be a potential biomarker of diabetic bone disease in the initial stages of the diagnosis of the disease [73]. Here, FNDC5 is linked to osteoporosis.